C-C motif chemokine ligand 13 (CCL13)

C-C motif chemokine ligand 13 (CCL13), also known as monocyte chemoattractant protein 4 (MCP-4), is a member of the CC chemokine family of secreted signaling proteins involved in the recruitment (chemotaxis) of immune cells, including monocytes, eosinophils, basophils, and lymphocytes, during inflammatory and immune responses[1][2][3]. CCL13 binds to chemokine receptors such as CCR1, CCR2, CCR3, CCR5, and CCR11 to mediate migration and activation of these cells and is expressed in various tissues and cell types[1][2]. CCL13 is implicated in the pathogenesis of asthma, allergic diseases, rheumatoid arthritis, atherosclerosis, and some malignancies, where it promotes inflammatory cell infiltration and tissue damage[1]. It can also exhibit antimicrobial activity against certain bacteria[1]. CCL13 levels serve as a disease biomarker in certain settings, and targeting the CCL13 axis is considered a potential strategy for modulating immune and inflammatory diseases, although its overlapping function with other chemokines poses significant therapeutic challenges[1][2].

Other names

MCP-4Monocyte chemoattractant protein 4Monocyte chemotactic protein 4CK-beta-10CKb10NCC-1NCC1SCYA13SCYL1Small-inducible cytokine A13New CC chemokine 1

Blockade of chemokine receptors (CCR1, CCR2, CCR3, CCR5); Inhibition of upstream cytokines (such as IL-13, IL-4) to reduce CCL13 release; Janus kinase/spleen tyrosine kinase (JAK/SYK) pathway inhibition; Inhibition of TLR4-mediated signaling; Inhibition of chemokine-mediated Ca²⁺ influx